Nine CSL leaders offer their advice for seizing opportunities and designing your own career path.

CSL Chief Sustainability Officer Jeffrey Ball looks ahead to Earth Day on April 22 and shares highlights, including CSL’s renewable-linked power purchase agreement in Australia and the company’s plan to submit emissions targets for validation in July.

Paul shares his perspectives on his first year as CSL’s CEO, how CSL chooses its areas of focus, CSL’s strategy on sustainability and more.

CSL Behring leaders are helping shape the conversation in Europe about how to give patients access to potentially game-changing treatments.

Three CSL leaders joined the Alliance for mRNA Medicines on a trip to the nation’s capital to discuss the future of mRNA technologies.

CSL’s Debbie Drane recently spoke on a panel about how to keep momentum going following a record-setting year for cell and gene therapies.

With a new CEO, a new subsidiary, a newly approved gene therapy and three R&D centers under construction on three different continents, change is coming fast for CSL Limited.

CSL Head of R&D and Chief Medical Officer Bill Mezzanotte is interviewed in the Australian Financial Review (Subscription Required)